Clinical trial Recruiting at 1 site Observational Ages 30 to 75

Registry for understanding Parkinson's disease in China

Official title: The Chinese DENOVO Parkinson's Disease Registry

Run by Xiangya Hospital of Central South University · NCT05767151 · Data updated 2026-11-12

This study looks at how Parkinson's disease affects patients in China over time to see if certain signs can help predict how the disease will progress.

Quick facts

Study typeObservational
Ages30 Years to 75 Years
SexAll
Enrollment300 (estimated)
SponsorXiangya Hospital of Central South University
Academic / other
Locations1 site (Changsha, Hunan)
StatusRecruiting
StartedJanuary 1, 2021
Main results expectedJanuary 1, 2031
Study endsJanuary 1, 2031
Registry record updatedMarch 14, 2023
Trial IDNCT05767151 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are newly diagnosed Parkinson's disease patients aged 30 to 75 with a disease duration of two years or less.

Probably not a fit

Patients with cognitive impairment or those already receiving antiparkinsonian therapy will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the clinical characteristics and progression of Parkinson's disease (PD) in a longitudinal cohort of patients in China. It focuses on identifying biomarkers that can predict disease evolution and prognosis, addressing the heterogeneity of PD symptoms and progression rates. Data will be collected at baseline and during routine follow-up visits, including detailed patient histories and environmental factors. The study seeks to enhance understanding of PD's clinical features and potential genetic and environmental influences.

Why it matters

Potential benefit: If successful, this study could lead to better prediction of Parkinson's disease progression and more personalized treatment approaches for patients.

How similar studies have gone: Other studies have shown promise in identifying biomarkers for Parkinson's disease, but this specific approach focusing on a Chinese cohort is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Participants were diagnosed by MDS Clinical Diagnostic Criteria for PD
2. Disease duration ≤ 2 years at baseline
3. Hoehn-Yahr stage ≤2 at baseline
4. The age of PD patients ranges from 30 to 75 years old
5. Participants were naive to antiparkinsonian therapy
6. Able to Written informed consent

Exclusion Criteria:

1. Participants were diagnosed with parkinsonism-syndrome
2. Participants were treated with antiparkinsonian drugs at baseline
3. Participants with cognitive impairment
4. Unable to Written informed consent

Where it's running

  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.